Anti-avb6 antibodies and antibody-drug conjugates
AssigneeSeagen Inc.
InventorsMaureen Ryan, Lori Westendorf, Eric Bradley Meyer, Heather Jean Kostner
Life of this patent
Estimating the term…
Abstract
Provided are novel anti-αvβ6 antibodies and antibody-drug conjugates and methods of using such anti-αvβ6 antibodies and antibody-drug conjugates to treat cancer.
Claims42
An isolated anti-αvβ6 antibody, or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises:
- (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:31;
- (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:32;
- and
- (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:33;
- and
- wherein the light chain variable region comprises:
- (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:37;
- (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:42;
- and
- (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:39
- wherein the CDRs are determined by Kabat.
An isolated anti-αvβ6 antibody, or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises:
- (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:34;
- (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:35;
- and
- (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:36;
- and
- wherein the light chain variable region comprises:
- (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:43;
- (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:44;
- and
- (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:45
- wherein the CDRs are determined by IMGT.
An antibody-drug conjugate comprising isolated anti-αvβ6 antibody conjugated to vcMMAE, wherein the antibody has a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
- 6 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:
- 17, and wherein the antibody-drug conjugate has the structure:
- wherein Ab is the antibody and p denotes a number from 1 to 16.
Dependencies are inferred from the claim text.